Arcus’s highest priority is to execute on its ongoing Phase 3 trial and overall development plan aimed at establishing casdatifan as the standard-of-care and backbone therapy for clear cell renal cell ...

Samsung Bioepis pursues direct sales by weighing Organon acquisition to boost profits Samsung Bioepis weighs buying Organon ...

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Analysts are intrested in these 5 stocks: ( ($CWAN) ), ( ($HTBK) ), ( ($OVID) ), ( ($MCFT) ) and ( ($WHWK) ). Here is a breakdown of their recent ...

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

Switching to a second TNF inhibitor in inflammatory bowel disease may raise the risk for immune-mediated inflammatory ...

Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...